
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

71664
10.1038/s41598-024-71664-0
Article
Association between family economic situation and serum PFAS concentration in American adults with hypertension and hyperlipemia
Zhou Xingye 1
Wang Xingren 2
Ou Tingting 2
Huang Lei 3
He Bin binhe898@189.cn

4
1 grid.443397.e 0000 0004 0368 7493 Hospital Infection Management and Disease Prevention and Control Department, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan China
2 https://ror.org/02yr91f43 grid.508372.b Department for Endemic and Chronic Disease Control, Hainan Provincial Center for Disease Control and Prevention, Haikou, Hainan China
3 https://ror.org/01tjgw469 grid.440714.2 0000 0004 1797 9454 School of Public Health and Health Management, Gannan Medical University, Ganzhou, Jiangxi China
4 https://ror.org/02yr91f43 grid.508372.b Hainan Provincial Center for Disease Control and Prevention, 40 Haifu Avenue, Haikou, Hainan China
5 9 2024
5 9 2024
2024
14 207997 3 2024
29 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Although there is an association between income status and concentration of perfluoroalkyl and polyfluoroalkyl substance (PFAS), the association remains uncertain in patients with hypertension, hyperlipidemia, and comorbidities. Data from the 2013–2016 National Health and Nutrition Examination Survey were analyzed. A total of 2665 adults were included, and the data included participants' serum PFAS (perfluorooctanoic acid [PFOA], perfluorononaic acid, perfluorodecanoic acid, perfluoroundecanoic acid, perfluorohexane sulfonic acid, and perfluorooctane sulfonic acid) levels and selected covariates. Multivariate linear regression models were used to examine the association between the ratio of family income to poverty (PIR) and individual serum PFAS concentrations in the hypertensive and/or hyperlipidemia groups after adjusting for covariates. The potential effects of sex and age on the results were explored using stratified analysis. A mediating effect model was used to explore the mediating effects of body mass index (BMI) and waist circumference on the association results. After adjusting for potential confounders, for hyperlipidemia and comorbidities (hypertension and hyperlipidemia), serum levels of multiple common PFAS increased by 0.09% (95%Confidence interval [CI] 0.02–0.15%) to 0.13% (95%CI 0.08–0.19%) and 0.10% (95%CI 0.02–0.17%) to 0.12% (95%CI 0.06–0.18%), respectively, with each 1% increase in PIR. The covariate model and stratified analyses results suggested the potential effects of different covariates such as age and sex, leading to changes in the statistical significance of the association results. BMI significantly mediated the effect of PIR on PFOA in hyperlipidemia (13%, P < 0.001). Household income in adults with hyperlipidemia and comorbidities positively correlated with serum PFAS concentration in the United States. Obesity played an indispensable mediating role in the association between economic income and PFAS concentration.

Keywords

PFAS
U.S.
Income
Hypertension
Hyperlipemia
Obesity
Subject terms

Risk factors
Environmental impact
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

A recent study analyzed the hotspot evolution and research trends of a variety of emerging pollutants over the past 20 years and found that perfluoroalkyl and polyfluoroalkyl substances (PFAS) are among currently the most important emerging pollutants1. PFAS are organic pollutants. These chemicals are lipophilic, hydrophilic, and thermochemically stable2. The chemical stability of single-carbon and carbon–fluorine bonds makes them difficult to degrade in the environment3. They are commonly used in industrial and commercial processes as organic surfactants in electronics, surface coatings, and firefighting foams4. Among the various PFAS that have been identified so far, National Health and Nutrition Examination Survey (NHANES) regularly detects the concentrations of more than 10 serum PFAS (containing isomers) in American household populations, including perfluorooctanoic acid (PFOA), perfluorononaic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnDA), perfluorohexane sulfonic acid (PFHxS), and perfluorooctane sulfonic acid (PFOS) on a 2-year cycle.

As an important part of the justice movement, the environmental justice theory proposes that there are racial and class differences in poison damage5. Compared to other groups, residents in poor areas tend to be more exposed to environmental pollution, making them more vulnerable to the adverse effects of the pollutants. Perhaps unequal exposure to toxic substances is not only a matter of distance from the pollutant sources but also involves factors such as community, race, industrial change, class composition, and suburbanization6,7. However, Glynn et al.’s study showed the opposite conclusion, showing that participants born in high-income countries had higher serum concentrations of PFAS than participants born in other income levels8. Interestingly, current research on PFAS and population health has focused on vulnerable populations, such as children9,10, adolescents10,11, pregnant women12,13, and older adults14. In addition, it is easy to overlook that people who suffer from a chronic disease or even suffer from multiple chronic diseases are also vulnerable to environmental pollutants, and they are often considered to be more vulnerable to the negative effects of environmental pollutants due to their reduced resistance to diseases15. Hypertension and hyperlipidemia are often associated and occur simultaneously. Comorbidities (≥ 2 chronic diseases) are common among middle-aged and older patients in community health centers, with the most common patterns being hyperlipidemia-hypertension16. Comorbidities are often associated with greater disability and a higher treatment burden. Simultaneously, adults with complex and sick patterns have difficulty in performing self-management tasks. However, only a few studies have focused on this topic.

Obesity is closely related to the economy. The economic burden of obesity is enormous17. Previous research has shown an association between higher socioeconomic levels in adulthood and lower levels of fat in high-income countries. However, an association in the opposite direction has only been observed in middle-income countries18. PFAS have a long half-life and can easily cross the placental barrier from the pregnant woman to the fetus19–21. There is evidence that prenatal exposure of a pregnant woman is positively associated with PFAS and the body mass index (BMI) or waist circumference of her child during adolescence22,23. Therefore, we hypothesized that there would be a positive association between serum PFAS concentration and obesity. Moreover, owing to the close relationship between obesity and the economy, obesity may have a certain degree of mediating effect on the process of influencing serum PFAS concentrations by economic level.

In this study, we aimed to measure the association between serum PFAS concentration and the ratio of family income to poverty (PIR) in hypertensive and hyperlipidemic populations and to assess the potential influence of sex and age on these associations. Simultaneously, we established a mediating effect model to explore the mediating effect of BMI and waist circumference on the possible influence of PIR on serum PFAS concentration, to further explore the internal reasons for the possible influence of socioeconomic status on serum PFAS concentration.

Methods

Research design and population

This study summarizes the cross-sectional data from the 2015 to 2018 NHANES cycles. The National Health and Nutrition Examination Survey (NHANES) is a population-based national survey conducted every 2 years that measures the health and nutritional status of non-institutionalized adults, civilians, children, and adolescents in the United States. The Centers for Disease Control and Prevention have described the detailed research procedures for NHANES24. To avoid growth and development disturbances, we included only survey participants aged over 20 years while screening for complete data on serum PFAS concentrations, PIR (defined as the ratio of a family's self-reported income to the appropriate poverty line for a family25), and covariates (see the Covariates section for details). Based on the study design, we excluded missing information and age-ineligible participants and included 2665 adults. Further details are shown in Fig. 1.Fig. 1 Study design flowchart and reasons for excluded participants.

Population grouping and disease definition

The participants were divided into four groups based on their health status: no disease (without hypertension and hyperlipidemia), hypertension (with hypertension but without hyperlipidemia), hyperlipidemia (with hyperlipidemia but without hypertension), and comorbidities (with hypertension and hyperlipidemia). The presence of one of the following conditions was considered hypertension: systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg, or self-reported current use of blood pressure medications. The presence of one of the following conditions is considered to be hyperlipidemia: TC ≥ 5.18 mmol/L or HDL-C ≤ 1.04 mmol/L or use of high cholesterol drugs.

Measurement of PFAS in serum

PFAS were quantitatively detected using online solid-phase extraction coupled with high-performance liquid chromatography-turboionspray ionization-tandem mass spectrometry (SPE-HPLC-TIS-MS/MS). Six common PFAS were used as outcome measures: PFOA, PFNA, PFDA, PFUnDA, PFHxS, and PFOS. The PFOA and PFOS concentrations were calculated as the sum of their isomer concentrations. In each cycle, concentrations below the detection limit were replaced by the detection limit divided by the square root of 2. Detailed quality control information is available from the NHANES and Nutrition Examination Survey Laboratory Procedure Manual.

Covariates and mediators

Demographic covariates included in this study were obtained through a report questionnaire, including age (continuous), sex (male or female), race or ethnicity (Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black, or Other Race-Including Multi-Racial), Six month time period (November 1 through April 30 or May 1 through October 31), and adult educational level (below secondary school, secondary school, high school graduate, college degree, and college graduate or above). Physical parameters such as height, weight, and waist circumference were measured by trained health technicians. The mediating variables included in this study were BMI and waist circumference, which reflect the obesity status of the participants.

Statistical analysis

Descriptive statistics were calculated for serum PFAS concentrations in the participants divided into four groups based on their health status. The Kruskal–Wallis test was used to determine whether participants in the four groups had the same serum PFAS concentrations. The concentrations between the two groups were further compared based on the average rank of the samples in each analysis group. Multivariate linear regression models were used to examine the relationship between the PIR and individual serum PFAS concentrations in patients with different diseases. After logarithmic conversion of the independent and dependent variables, the results of the regression analysis were expressed as the percentage change in serum PFAS concentration, which may have been caused by a 1% increase in PIR. For the overall analysis, we fitted 24 regression models, each combining four different health conditions and six different PFAS. The independent variables used in each model were sex (continuous variable), age (continuous variable), PIR (continuous variable), race (categorical variable), inspection time (categorical variable), and educational level (categorical variable). Subsequently, to explore the potential effects of different gender and age, we conducted a subgroup analysis, which was classified into four subgroups: males, females, older adults (≥ 60 years old), and young adults (20–59 years old). Similarly, each subgroup was fitted to 24 regression models, each with independent variables similar to those used in the overall analysis. Simultaneously, models with three different covariates were fitted (no common covariates were included, some common covariates were included, and all common covariates were included) to test the influence of model covariates on the regression results.

Mediation analysis is an ideal strategy for elucidating the ways in which independent variables are used against dependent variables and for elucidating statistical evidence for mechanism analysis26,27. In this study, we quantitatively calculated the mediating effect of obesity indicators (BMI or waist circumference) in the regression process through a mediating analysis. The direct effect represents the direct relationship between the PIR and serum PFAS concentrations in different groups of patients. Indirect effects represent the relationship between the PIR mediated by obesity (BMI or waist circumference) and serum PFAS concentrations. The mediated proportion represents the percentage of mediating effects. The combined effect was expressed as the sum of the direct and indirect effects. These can be represented statistically by a set of linear regressions.1 Yi=α1+cXi+β1Zi+εi

2 Mi=α2+aXi+β2Zi+εi

3 Yi=α3+bMi+cXi+β3Zi+εi

Estimates of indirect effects rely on the values of the remaining two independent regression models, so the results of significance tests and standard error can be obtained by bootstrapping. Therefore, bootstrapping with 1000 replications was performed for each expected mediating variable and PFAS concentration, controlling for confounding factors, to examine the mediating effect9.

A sensitivity analysis was used to further evaluate the robustness of the regression models. Participants with extreme PFAS concentrations of 1% were excluded from each fitted model. In the remaining participants, the association between the PIR and serum PFAS concentrations was assessed again. In this study, R 4.3.1 software was used for statistical analysis. P < 0.05 was considered statistically significant.

Results

Participant characteristics

As shown in Table 1, a total of 2665 participants were included in this study. Of these, 789 (29.6%) did not have hypertension or hyperlipidemia (no disease group), 224 (8.4%) had hypertension but no hyperlipidemia (hypertension group), 909 (34.1%) had hyperlipidemia but no hypertension (hyperlipidemia group), and 743 (27.9%) had hypertension and hyperlipidemia (comorbidity group). The Kruskal–Wallis test results indicated that the concentrations of PFAS in the four groups were different. Subsequently, according to the analysis of the average rank of PFAS concentrations in each group of samples, the concentrations of PFAS in the serum were the highest in the comorbidity group. For PFOA, PFNA, and PFHxS, there were no statistically significant differences in serum concentrations between participants in the hypertension and hyperlipidemia groups; however, they were higher than those in the no-disease group. For PFDA and PFUnDA, there were no statistically significant differences in serum concentrations among the no disease, hypertension, and hyperlipidemia groups. Serum PFOS concentrations in the hypertension group were higher than those in the hyperlipidemia group, and both were higher than those in the no disease group.Table 1 The median concentration of PFAS (ng/mL) in the serum of the participants.

	N (weighted %)	PFOA	PFNA	PFDA	PFUnDA	PFHxS	PFOS	
Overall	
 No Diseases	789 (29.6)	1.37	0.5	0.2	0.1	0.9	3.9	
 Hypertension	224 (8.4)	1.57	0.5	0.2	0.1	1.2	5.6	
 Hyperlipidemia	909 (34.1)	1.57	0.5	0.2	0.1	1.3	5	
 Comorbidity	743 (27.9)	1.77	0.7	0.2	0.1	1.5	7.1	
 P		< 0.05a	< 0.05a	< 0.05b	< 0.05b	< 0.05a	< 0.05c	
Gender	
 Male	
  No Diseases	318 (24.5)	1.67	0.5	0.2	0.1	1.6	6	
  P (F)		< 0.05	< 0.05	< 0.05	0.40	< 0.05	< 0.05	
  Hypertension	107 (8.2)	1.67	0.5	0.2	0.1	1.6	7	
  P (F)		< 0.05	0.11	0.54	0.28	< 0.05	< 0.05	
  Hyperlipidemia	508 (39.2)	1.77	0.6	0.2	0.1	1.6	6.4	
  P (F)		< 0.05	< 0.05	< 0.05	0.63	< 0.05	< 0.05	
  Comorbidity	364 (28.1)	1.97	0.7	0.2	0.1	1.7	8.6	
  P (F)		< 0.05	0.64	0.53	0.80	< 0.05	< 0.05	
 Female	
  No Diseases	471 (34.4)	1.07	0.4	0.2	0.1	0.6	2.8	
  Hypertension	117 (8.6)	1.47	0.5	0.2	0.07	1	4.7	
  Hyperlipidemia	401 (29.3)	1.27	0.5	0.2	0.1	0.8	3.5	
  Comorbidity	379 (27.7)	1.57	0.7	0.2	0.1	1.2	5.7	
Age	
 20–59	
  No Diseases	709 (40.1)	1.27	0.4	0.2	0.1	0.8	3.6	
  P (OA)		< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	
  Hypertension	109 (6.2)	1.27	0.5	0.2	0.1	1.1	4.1	
  P (OA)		< 0.05	< 0.05	0.10	0.97	< 0.05	< 0.05	
  Hyperlipidemia	683 (38.6)	1.37	0.5	0.2	0.1	1.2	4.4	
  P (OA)		< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	
  Comorbidity	267 (15.1)	1.47	0.6	0.2	0.1	1.1	5.2	
  P (OA)		< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	
 60+	
  No Diseases	80 (8.9)	1.87	0.8	0.2	0.1	1.4	6.35	
  Hypertension	115 (12.8)	1.97	0.6	0.2	0.1	1.5	7.6	
  Hyperlipidemia	226 (25.2)	1.97	0.7	0.2	0.1	1.7	8.1	
  Comorbidity	476 (53.1)	1.935	0.7	0.2	0.1	1.65	8.45	
aMeant that there was no statistical difference in concentration between the hypertension and hyperlipidemia groups (P = 0.70–0.86), and there was a difference between any two other groups (P < 0.05). bIndicated that there was no statistical difference in the concentration among the disease-free group, the hypertension group and the hyperlipidemia group (P = 0.48–0.61), and there was a difference between the comorbidity group and the other three groups (P < 0.05). cRepresented a statistical difference in concentration between any two groups (P < 0.05). F represented compared with females. OA represented compared with older adults.

Significant values are in bold.

Correlation analysis

The results of the pairwise spearman correlation coefficient showed that the correlation coefficient between the selected PFAS ranged from 0.136 to 0.756 (Fig. 2).Fig. 2 Correlation analysis of PFAS.

Multiple linear regression models

Overall analysis

As shown in Table 2, serum PFAS concentrations were positively correlated with the PIR in the no disease, hyperlipidemia, and comorbidity groups. More specifically, for every 1% increase in PIR in the no-disease group, serum concentrations of PFOA, PFNA, and PFHxS increased by 0.10% (95%CI 0.04–0.16%), 0.08% (95%CI 0.01–0.16%), and 0.11% (95%CI 0.03–0.18%), respectively. The serum concentrations of PFOA, PFNA, PFDA, PFUnDA, and PFHxS increased by 0.10% (95%CI 0.04–0.15%), 0.09% (95%CI 0.02–0.16%), 0.10% (95%CI 0.03–0.17%), 0.08% (95%CI 0.01–0.15%), and 0.09% (95%CI 0.02–0.15%), respectively, when PIR increased by 1% in hyperlipidemia group. In comorbidity group, the serum concentrations of PFOA, PFNA, PFDA, PFUnDA, PFHxS, and PFOS increased by 0.09% (95%CI 0.03–0.15%), 0.07% (95%CI 0.01–0.14%), 0.13% (95%CI 0.04–0.21%), 0.12% (95%CI 0.04–0.19%), 0.10% (95%CI 0.02–0.18%), and 0.11% (95%CI 0.03–0.19%), respectively, for every 1% increase in PIR.Table 2 After adjusting for age, sex, race, survey time, and education level, the percentage change in the concentration of PFAS as the income poverty ratio increased by 1%.

	PFOA	PFNA	PFDA	PFUnDA	PFHxS	PFOS	
Overall	
 No Diseases	0.10 (0.04, 0.16)	0.08 (0.01, 0.16)	0.01 (− 0.07, 0.08)	− 0.01 (− 0.08, 0.07)	0.11 (0.03, 0.18)	0.03 (− 0.03, 0.09)	
 Hypertension	0.07 (− 0.06, 0.19)	0.08 (− 0.06, 0.21)	0.14 (0.00, 0.29)	0.11 (− 0.03, 0.24)	0.04 (− 0.12, 0.20)	0.07 (− 0.08, 0.23)	
 Hyperlipidemia	0.10 (0.04, 0.15)	0.09 (0.02, 0.16)	0.10 (0.03, 0.17)	0.08 (0.01, 0.15)	0.09 (0.02, 0.15)	0.04 (− 0.02, 0.11)	
 Comorbidity	0.09 (0.03, 0.15)	0.07 (0.01, 0.14)	0.13 (0.04, 0.21)	0.12 (0.04, 0.19)	0.10 (0.02, 0.18)	0.11 (0.03, 0.19)	
Gender	
 Male	
  No Diseases	0.08 (0.00, 0.16)	0.07 (− 0.04, 0.17)	− 0.01 (− 0.12, 0.09)	− 0.05 (− 0.16, 0.06)	0.11 (0.01, 0.22)	0.02 (− 0.07, 0.11)	
  Hypertension	0.10 (− 0.07, 0.28)	0.17 (0.00, 0.34)	0.19 (− 0.01, 0.38)	0.10 (− 0.08, 0.28)	0.01 (− 0.20, 0.22)	0.14 (− 0.07, 0.35)	
  Hyperlipidemia	0.06 (− 0.01, 0.13)	0.06 (− 0.03, 0.15)	0.07 (− 0.02, 0.17)	0.07 (− 0.02, 0.16)	0.08 (0.00, 0.17)	0.05 (− 0.03, 0.14)	
  Comorbidity	0.16 (0.07, 0.24)	0.13 (0.04, 0.22)	0.17 (0.05, 0.28)	0.16 (0.05, 0.27)	0.18 (0.06, 0.29)	0.21 (0.10, 0.32)	
 Female	
  No Diseases	0.11 (0.03, 0.20)	0.09 (− 0.01, 0.19)	0.02 (− 0.09, 0.12)	0.03 (− 0.07, 0.13)	0.08 (− 0.03, 0.19)	0.03 (− 0.06, 0.13)	
  Hypertension	0.03 (− 0.16, 0.23)	− 0.04 (− 0.26, 0.18)	0.07 (− 0.17, 0.30)	0.11 (− 0.10, 0.32)	0.06 (− 0.18, 0.30)	− 0.05 (− 0.30, 0.19)	
  Hyperlipidemia	0.11 (0.03, 0.19)	0.09 (− 0.01, 0.19)	0.13 (0.02, 0.23)	0.09 (− 0.01, 0.19)	0.07 (− 0.03, 0.16)	0.01 (− 0.08, 0.10)	
  Comorbidity	0.03 (− 0.06, 0.11)	0.03 (− 0.08, 0.13)	0.09 (− 0.03, 0.20)	0.08 (− 0.03, 0.18)	0.02 (− 0.08, 0.12)	0.02 (− 0.09, 0.13)	
Age	
 20–59	
  No Diseases	0.12 (0.06, 0.18)	0.10 (0.03, 0.18)	0.02 (− 0.06, 0.10)	0.00 (− 0.07, 0.08)	0.10 (0.02, 0.18)	0.06 (− 0.01, 0.13)	
  Hypertension	0.05 (− 0.11, 0.21)	0.13 (− 0.05, 0.31)	0.23 (0.03, 0.44)	0.13 (− 0.07, 0.32)	0.06 (− 0.13, 0.26)	0.15 (− 0.06, 0.36)	
  Hyperlipidemia	0.10 (0.03, 0.16)	0.09 (0.01, 0.17)	0.10 (0.02, 0.18)	0.07 (0.00, 0.15)	0.10 (0.03, 0.18)	0.08 (0.00, 0.15)	
  Comorbidity	0.19 (0.09, 0.29)	0.13 (0.02, 0.24)	0.16 (0.03, 0.29)	0.09 (− 0.03, 0.21)	0.22 (0.10, 0.35)	0.23 (0.10, 0.36)	
 60+	
  No Diseases	0.07 (− 0.17, 0.30)	0.26 (− 0.01, 0.52)	0.17 (− 0.12, 0.45)	0.07 (− 0.24, 0.37)	0.30 (0.03, 0.57)	0.12 (− 0.10, 0.35)	
  Hypertension	0.15 (− 0.04, 0.35)	0.10 (− 0.10, 0.29)	0.11 (− 0.08, 0.31)	0.12 (− 0.06, 0.30)	0.09 (− 0.16, 0.34)	0.08 (− 0.14, 0.30)	
  Hyperlipidemia	0.14 (0.04, 0.23)	0.17 (0.04, 0.29)	0.17 (0.02, 0.31)	0.16 (0.02, 0.31)	0.08 (− 0.04, 0.21)	0.04 (− 0.08, 0.16)	
  Comorbidity	0.05 (− 0.03, 0.13)	0.05 (− 0.05, 0.14)	0.11 (0.01, 0.21)	0.14 (0.04, 0.24)	0.06 (− 0.04, 0.15)	0.07 (− 0.04, 0.17)	
Bold meant statistically significant (P < 0.05). PFOA, perfluorooctanoic acid; PFNA, perfluorononaic acid; PFDA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; PFHxS, perfluorohexane sulfonic acid; PFOS, perfluorooctane sulfonic acid.

Regression models of different covariates

As shown in Fig. 3, three linear regression models were established using different covariates. Associations between the PIR and serum PFAS concentrations in the no disease, hyperlipidemia, and comorbidity groups were observed in all three models. More specifically, for model 1, serum perfluorooctanoic acid concentrations increased by 0.16% (95%CI 0.10–0.21%) for every 1% increase in PIR in the disease-free population. In Models 2 and 3, the effect size decreased from 0.16 to 0.15% (95%CI 0.09–0.20%) and 0.10% (95%CI 0.04–0.16%), respectively. For more detailed data, see Tables A1 and A2 in the supplementary files.Fig. 3 Percentage change in serum PFAS with each 1% increase in PIR, considering the different covariate models. PFOA, perfluorooctanoic acid; PFNA, perfluorononaic acid; PFDA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; PFHxS, perfluorohexane sulfonic acid; PFOS, perfluorooctane sulfonic acid; PIR, the ratio of family income to poverty. Model 1 did not adjust for confounding factors, Model 2 adjusted for age and sex, and Model 3 adjusted for age, sex, race, survey time, and education level.

Gender difference

Association between income and PFAS concentrations in different sexes and ages: Serum PFAS concentrations were positively correlated with PIR in men in the no-disease and comorbidity groups. In the no-disease group, for every 1% increase in the PIR in men, the serum concentration of PFHxS increased by 0.11% (95%CI 0.01–0.22%). In comorbidity group, for every 1% increase in PIR in men, the serum concentrations of PFOA, PFNA, PFDA, PFUnDA, PFHxS, and PFOS increased by 0.16% (95%CI 0.07–0.24%), 0.13% (95%CI 0.04–0.22%), 0.17% (95%CI 0.05–0.28%), 0.16% (95%CI 0.05–0.27%), 0.18% (95%CI 0.06–0.29%), and 0.21% (95%CI 0.10–0.32%), respectively.

Serum PFAS concentrations were positively correlated with the PIR in women in the no disease and hyperlipidemia groups. In no disease group, for every 1% increase in PIR in women, the serum concentration of PFOA increased by 0.11% (95%CI 0.03–0.20%). In the hyperlipidemia group, for every 1% increase in the PIR in women, the serum concentrations of PFOA and PFDA increased by 0.11% (95%CI 0.03–0.19%) and 0.13% (95%CI 0.02–0.23%), respectively.

Age difference

A positive correlation between serum PFAS concentrations and PIR was observed in young adults in the no disease, hypertension, hyperlipidemia, and comorbidity groups. In no disease group, for every 1% increase in PIR in young adults, the serum concentrations of PFOA, PFNA, and PFHxS increased by 0.12% (95%CI 0.06–0.18%), 0.10% (95%CI 0.03–0.18%), and 0.10% (95%CI 0.02–0.18%), respectively. In hypertension group, for every 1% increase in PIR in young adults, the serum concentration of PFDA increased by 0.23% (95%CI 0.03–0.44%). In hyperlipemia group, for every 1% increase in PIR in young adults, the serum concentrations of PFOA, PFNA, PFDA, PFHxS, and PFOS increased by 0.10% (95%CI 0.03–0.16%), 0.09% (95%CI 0.01–0.17%), 0.10% (95%CI 0.02–0.18%), 0.22% (95%CI 0.10–0.35%), and 0.23% (95%CI 0.10–0.36%), respectively. In comorbidity group, for every 1% increase in PIR in young adults, the serum concentrations of PFOA, PFNA, PFDA, PFHxS, and PFOS increased by 0.19% (95%CI 0.09–0.29%), 0.13% (95%CI 0.02–0.24%), 0.16% (95%CI 0.03–0.29%), 0.22% (95%CI 0.10–0.35%), and 0.23% (95%CI 0.10–0.36%), respectively.

A positive correlation between serum PFAS concentration and PIR was observed in older adults in the no disease, hyperlipidemia, and comorbidity groups. In no disease group, for every 1% increase in PIR in the older adults, the serum concentration of PFHxS increased by 0.30% (95%CI 0.03–0.57%). In the hyperlipidemia group, for every 1% increase in the PIR in the older adults, the serum concentrations of PFOA, PFNA, PFDA, and PFUnDA increased by 0.14% (95%CI 0.04–0.23%), 0.17% (95%CI 0.04–0.29%), 0.17% (95%CI 0.02–0.31%), and 0.16% (95%CI 0.02–0.31%), respectively. In comorbidity group, for every 1% increase in PIR in the older adults, the serum concentrations of PFDA and PFUnDA increased by 0.11% (95%CI 0.01–0.21%) and 0.14% (95%CI 0.04–0.24%), respectively.

Mediating effect

Mediation analyses were performed to examine whether the association between PIR and PFOA and PFNA was mediated by BMI (Figs. 4 and A1). In hyperlipidemia group, BMI was found to mediate 21.5% of the association between PIR and PFOA, and 11.7% of the association between PIR and PFNA. However, the significant mediating role of BMI was not observed in either no disease group, hypertension group or comorbidities group. Subsequently, an empirical test of the mediating effect was conducted (Table A3).Fig. 4 Mediating effects of obesity. *P < 0.05. **P < 0.01. ***P < 0.001. (A) represented no disease group, (B) represented hypertension group, (C) represented hyperlipidemia group, (D) represented comorbidities group. PIR, the ratio of family income to poverty. BMI, body mass index; PFOA, perfluorooctanoic acid.

Sensitivity analysis

As shown in Table 3, the results remained robust in the sensitivity analysis. Specifically, the statistical significance of only 1 outcome changed from that of the 24 regression models fitted to the overall analysis. In the sensitivity analysis, the increase in serum PFDA concentration in the hypertension group changed from 0.14% (95%CI 0.00–0.29%) to 0.15% (95%CI 0.01–0.30%) with a 1% increase in the PIR.Table 3 Sensitivity analysis of the overall analysis.

	PFOA	PFNA	PFDA	PFUnDA	PFHxS	PFOS	
No Diseases	0.11 (0.05, 0.17)	0.08 (0.01, 0.16)	0.03 (− 0.05, 0.11)	0.00 (− 0.07, 0.08)	0.11 (0.03, 0.18)	0.04 (− 0.02, 0.11)	
Hypertension	0.08 (− 0.04, 0.21)	0.11 (− 0.03, 0.24)	0.15 (0.01, 0.30)	0.12 (− 0.02, 0.26)	0.09 (− 0.07, 0.24)	0.12 (− 0.04, 0.27)	
Hyperlipidemia	0.09 (0.04, 0.15)	0.08 (0.01, 0.15)	0.12 (0.05, 0.20)	0.08 (0.01, 0.15)	0.08 (0.01, 0.15)	0.04 (− 0.03, 0.10)	
Comorbidity	0.08 (0.02, 0.15)	0.07 (0.01, 0.14)	0.13 (0.04, 0.21)	0.13 (0.05, 0.21)	0.09 (0.02, 0.18)	0.11 (0.02, 0.19)	
Bold meant statistically significant (P < 0.05). PFOA, perfluorooctanoic acid; PFNA, perfluorononaic acid; PFDA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; PFHxS, perfluorohexane sulfonic acid; PFOS, perfluorooctane sulfonic acid.

Discussion

This study, which included 2665 U.S. adults, aimed to investigate the association between income and the emerging environmental pollutant PFAS in the serum of participants with hypertension and hyperlipidemia, to explore the potential effects of age and gender, and to analyze the mediating effect of obesity on income and PFAS concentrations.

This study observed that in people without hypertension and hyperlipidemia, serum PFAS concentrations increased by 0.06–0.16%, with a 1% increase in the income-poverty ratio. This finding is similar to that of previous studies. Using the NHANES, Jessica Tyrrell et al. observed a positive association between polyfluorinated compounds (PFOA, PFOS, and PFOA) and socioeconomic status in adults28. A meta-analysis showed that higher income was associated with higher PFAS concentrations, with an average increase in PFAS concentrations ranging from 10 to 14% when the household income of the study population doubled29. For PFOA, serum concentrations of PFAS were 21% (95%CI − 26 to − 14%) lower in the lowest quartile of adjusted household income than in the highest quartile30. However, a study that analyzed the relationship between serum PFAS concentrations and monthly income in 319 participants from suburban Seoul (Yeongseong and Suwon), Yeshan, and Busan in South Korea between 2006 and 2007 found no such association31. This may be due to differences in sample size, sampling location, and exposure history.

Perhaps, there are several studies that can be used to explain the relationship between income status and PFAS. Diet is a major source of human exposure to PFAS, with individuals of higher socioeconomic status tending to consume more fresh meat, fish, and vegetables, which are potential sources of PFOA32. Even within the same high-income countries, the underlying factors contributing to this growth may differ between the United States and Europe. In the United States, beef consumption may be the culprit, whereas in Europe, fish consumption may play a major role. However, differences in diet do not fully explain the potential for differences in PFAS concentrations in groups with different income levels. In addition, perfluorinated compounds tend to be found in expensive waterproof fabrics, which may explain their association with higher socioeconomic status. The serum concentrations of polyfluorinated compounds are also correlated with the levels of polyfluorinated compounds in office air33. People with a higher social status are more likely to work in white-collar offices, and higher exposure may explain the existence of a positive association to some extent. To uncover the relationship between social, economic, environmental, and health factors, and reduce human health inequalities, it is necessary to study the root causes of differences in PFAS exposure due to income levels. With this knowledge, we can raise awareness and encourage people to make informed choices to reduce their daily exposure to environmental pollutants.

In this study, the concentrations of PFOA, PFNA, PFHxS, and PFOS were higher in participants with hypertension than in those without hypertension. Among participants with hypertension, men had higher concentrations of PFOA, PFHxS, and PFOS than women. This is similar to the results of a recently published systematic review34 that included three cohort studies, two case–control studies, and eight cross-sectional studies for a meta-analysis evaluating the association between PFAS and hypertension. The study found that PFNA (OR = 1.11, 95%CI 1.04–1.19), PFOA (OR = 1.12, 95%CI 1.02–1.23), PFOS (OR = 1.19, 95%CI 1.06–1.34), and PFHxS (OR = 1.03, 95%CI 1.00–1.06) were significantly associated with hypertension. In addition, this study proposes that a clear gender difference is observed in individuals exposed to PFAS. Specifically, men exposed to PFNA, PFOA, and PFOS had a higher risk of developing hypertension than women. However, the underlying mechanism between PFAS exposure and hypertension remains poorly understood, and larger, higher-quality epidemiological studies, as well as in vivo and in vitro experiments, are needed to further elucidate this relationship. In addition to hypertension, PFAS may be associated with hyperlipidemia. Aker et al.35 examined the relationship between perfluoroalkyl acid mixtures and several cardiometabolic health outcomes and found that for every one-quarter increase in perfluoroalkyl acid mixtures, the total cholesterol, LDL, and HDL levels increased. The long-chain homologues PFNA, PFDA, and PFUnDA may be major contributors to lipid changes in vivo.

To our knowledge, this is the first study to report the potential mediating role of obesity in the relationship between income status and concentrations of PFAS in vivo. Our study also found that BMI may play a mediating role in the association of income status with concentrations of PFAS in vivo in hyperlipidemia group. There may be several studies that can be used to explain the mediating role of obesity. There may be several studies that can be used to explain the mediating role of obesity. On the one hand, studies have confirmed a significant negative correlation between obesity and PFAS36. On the other hand, BMI and income levels in adulthood are inversely related in high-income countries18. However, the mediating effect of obesity was not significant in people with hypertension. There is currently no plausible explanation for this result, which may be due to the positive association between PFAS and hyperlipidemia, but not the significant association between PFAS and hypertension36.

As emerging pollutants, PFAS have attracted considerable research attention in recent years, and the number of related studies is quite large. However, compared with the relatively concentrated focus on pregnant women and newborns in the field, the attention paid to adults with chronic diseases, such as hypertension and hyperlipidemia, is insufficient. Therefore, as a relatively rare study, this study examined the association between economic status and PFAS concentration in the disease population and attempted to reveal the potential influence of sex and age while exploring the mediating effect of obesity in the association using mediating models. A major advantage of this study is its rigorous sampling design, weighting scheme, and quality control based on NHANES. This allowed the study to obtain nationally representative cross-sectional data with large sample sizes to answer multiple association hypothesis questions of interest covering multiple subgroups. Our findings are robust and consistent across multiple sensitivity analyses.

This study has several limitations. First, the cross-sectional study design made it impossible to determine the timeliness of exposure and establish a causal relationship between the household income-poverty ratio and serum PFAS concentrations. Although we adjusted for as many demographic covariates and confounding variables as possible in our regression analysis, the effects of other unmeasured confounding variables could not be excluded. Finally, this study analyzed only six commonly investigated persistent PFAS in the population. Because the NHANES had little data on this, we were unable to assess exposure to other short chains and other PFAS compounds, which requires further research; however, our study provides a basis for future studies focusing on socioeconomic status and PFAS exposure in subhealthy chronic disease populations. Although our study revealed a significant positive association between household income and PFAS exposure in a vulnerable population with hyperlipidemia and comorbidities, our understanding remains incomplete due to existing studies. Further large longitudinal and experimental studies are needed to determine whether these associations are causal and to elucidate their potential mechanisms of action.

Conclusion

In summary, we observed a positive association between the PIR and serum PFAS levels in American adults with hyperlipidemia and comorbidities. Simultaneously, the potential effects of age and sex should not be ignored. In patients with hyperlipidemia, BMI significantly mediated the effect of the income-poverty ratio on PFOA. These results are similar to those of previous studies showing that income in the general population is positively correlated with PFAS concentrations. The environmental justice hypothesis states that groups with lower socioeconomic status tend to be more exposed to environmental pollutants. These studies clearly suggest that the environmental justice hypothesis is not a good description of PFAS exposure patterns. Given the widespread exposure, long half-lives, and health risks of PFAS, these findings may have important implications for interventions aimed at reducing their physical burden. Further prospective and experimental studies are needed to confirm or rule out a causal relationship between income and PFAS concentration in individuals with hypertension or hyperlipidemia and to investigate the mechanisms involved. This is an urgent and emerging topic in the fields of clinical medicine, public health, environmental science, and economics.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71664-0.

Author contributions

Xingye Zhou: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Writing—original draft, Writing—review and editing. Xingren Wang: Investigation, Methodology, Writing—original draft. Tingting Ou: Data curation, Investigation, Writing—review and editing. Lei Huang: Software, Writing—review and editing. Bin He (Corresponding Author): Conceptualization, Project administration.

Data availability

The datasets generated and/or analysed during the current study are available in the official website of the US Centers for Disease Control and Prevention (https://www.cdc.gov/nchs/nhanes/index.htm).

Competing interests

The authors declare no competing interests.

Ethical approval

The information of the investigators comes from the National Health and Nutrition Examination Survey. This project has strict ethics and informed consent, please visit the official website for details. https://www.cdc.gov/nchs/nhanes/participant/participant-about.htm

Consent to participate

The information of the investigators comes from the National Health and Nutrition Examination Survey. This project has strict ethics and informed consent, please visit the official website for details. https://www.cdc.gov/nchs/nhanes/participant/participant-benefit.htm

Consent to pubish

According to the National Health and Nutrition Examination Survey, the investigator’s name is not associated with any clinical information, only a unique survey participant ID. Responses from investigators are voluntary and confidential. For more information on participants’ privacy, please refer to the official website. https://www.cdc.gov/nchs/nhanes/participant/participant-confidentiality.htm.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Xingye Zhou and Xingren Wang.
==== Refs
References

1. Yu Y A bibliometric analysis of emerging contaminants (ECs) (2001–2021): Evolution of hotspots and research trends Sci. Total Environ. 2024 907 168116 10.1016/j.scitotenv.2023.168116 37884150
Yu, Y. et al. A bibliometric analysis of emerging contaminants (ECs) (2001–2021): Evolution of hotspots and research trends. Sci. Total Environ. 907, 168116 (2024).37884150 10.1016/j.scitotenv.2023.168116
2. Karaskova P Perfluorinated alkyl substances (PFASs) in household dust in Central Europe and North America Environ. Int. 2016 94 315 10.1016/j.envint.2016.05.031 27295048
Karaskova, P. et al. Perfluorinated alkyl substances (PFASs) in household dust in Central Europe and North America. Environ. Int. 94, 315 (2016).27295048 10.1016/j.envint.2016.05.031
3. Liu XT Fang ML Xu FP Chen D Characterization of the binding of per- and poly-fluorinated substances to proteins: A methodological review TrAC-Trends Anal. Chem. 2019 116 177 10.1016/j.trac.2019.05.017
Liu, X. T., Fang, M. L., Xu, F. P. & Chen, D. Characterization of the binding of per- and poly-fluorinated substances to proteins: A methodological review. TrAC-Trends Anal. Chem. 116, 177 (2019).10.1016/j.trac.2019.05.017
4. Xue X Gao N Xu F Toxicity of perfluooctane sulfonate (PFOS) and perfluorobutane sulfonate (PFBS) to Scenedesmus obliquus: Photosynthetic characteristics, oxidative damage and transcriptome analysis Environ. Pollut. 2022 315 120397 10.1016/j.envpol.2022.120397 36228843
Xue, X., Gao, N. & Xu, F. Toxicity of perfluooctane sulfonate (PFOS) and perfluorobutane sulfonate (PFBS) to Scenedesmus obliquus: Photosynthetic characteristics, oxidative damage and transcriptome analysis. Environ. Pollut. 315, 120397 (2022).36228843 10.1016/j.envpol.2022.120397
5. Environmental Protection Agency., Plan environmental justice 2014 (2014).
6. Brown P Race, class, and environmental health: A review and systematization of the literature Environ. Res. 1995 69 15 10.1006/enrs.1995.1021 7588491
Brown, P. Race, class, and environmental health: A review and systematization of the literature. Environ. Res. 69, 15 (1995).7588491 10.1006/enrs.1995.1021
7. Liddie JM Schaider LA Sunderland EM Sociodemographic factors are associated with the abundance of PFAS sources and detection in U.S. community water systems Environ. Sci. Technol. 2023 57 7902 10.1021/acs.est.2c07255 37184106
Liddie, J. M., Schaider, L. A. & Sunderland, E. M. Sociodemographic factors are associated with the abundance of PFAS sources and detection in U.S. community water systems. Environ. Sci. Technol. 57, 7902 (2023).37184106 10.1021/acs.est.2c07255
8. Glynn A Determinants of serum concentrations of perfluoroalkyl acids (PFAAs) in school children and the contribution of low-level PFAA-contaminated drinking water Environ. Sci.-Process. Impacts 2020 22 930 10.1039/C9EM00497A 32040098
Glynn, A. et al. Determinants of serum concentrations of perfluoroalkyl acids (PFAAs) in school children and the contribution of low-level PFAA-contaminated drinking water. Environ. Sci.-Process. Impacts 22, 930 (2020).32040098 10.1039/C9EM00497A
9. Domazet SL Exposure to perfluoroalkylated substances (PFAS) in relation to fitness, physical activity, and adipokine levels in childhood: The European youth heart study Environ. Res. 2020 191 110110 10.1016/j.envres.2020.110110 32871146
Domazet, S. L. et al. Exposure to perfluoroalkylated substances (PFAS) in relation to fitness, physical activity, and adipokine levels in childhood: The European youth heart study. Environ. Res. 191, 110110 (2020).32871146 10.1016/j.envres.2020.110110
10. Timmermann C Serum perfluoroalkyl substances, vaccine responses, and morbidity in a cohort of Guinea-Bissau children Environ. Health Perspect. 2020 128 87002 10.1289/EHP6517 32772733
Timmermann, C. et al. Serum perfluoroalkyl substances, vaccine responses, and morbidity in a cohort of Guinea-Bissau children. Environ. Health Perspect. 128, 87002 (2020).32772733 10.1289/EHP6517
11. Xie LN Serum concentrations of per-/polyfluoroalkyl substances and its association with renal function parameters among teenagers near a Chinese fluorochemical industrial plant: A cross-sectional study Environ. Pollut. 2022 302 119020 10.1016/j.envpol.2022.119020 35183668
Xie, L. N. et al. Serum concentrations of per-/polyfluoroalkyl substances and its association with renal function parameters among teenagers near a Chinese fluorochemical industrial plant: A cross-sectional study. Environ. Pollut. 302, 119020 (2022).35183668 10.1016/j.envpol.2022.119020
12. Lin C Associations of per- and polyfluoroalkyl substances and alternatives with reproductive hormones in women of childbearing age Int. J. Hyg. Environ. Health 2023 250 114158 10.1016/j.ijheh.2023.114158 36934548
Lin, C. et al. Associations of per- and polyfluoroalkyl substances and alternatives with reproductive hormones in women of childbearing age. Int. J. Hyg. Environ. Health 250, 114158 (2023).36934548 10.1016/j.ijheh.2023.114158
13. Mitro SD Pregnancy per- and polyfluoroalkyl substance concentrations and postpartum health in project viva: A prospective cohort J. Clin. Endocr. Metab. 2020 105 e3415 10.1210/clinem/dgaa431 32620010
Mitro, S. D. et al. Pregnancy per- and polyfluoroalkyl substance concentrations and postpartum health in project viva: A prospective cohort. J. Clin. Endocr. Metab. 105, e3415 (2020).32620010 10.1210/clinem/dgaa431
14. Park SK Ding N Han D Perfluoroalkyl substances and cognitive function in older adults: Should we consider non-monotonic dose-responses and chronic kidney disease? Environ. Res. 2021 192 110346 10.1016/j.envres.2020.110346 33068581
Park, S. K., Ding, N. & Han, D. Perfluoroalkyl substances and cognitive function in older adults: Should we consider non-monotonic dose-responses and chronic kidney disease?. Environ. Res. 192, 110346 (2021).33068581 10.1016/j.envres.2020.110346
15. Pan, J. et al. Temporal trend of serum perfluorooctanoic acid and perfluorooctane sulfonic acid among U.S. Adults with or without comorbidities in NHANES 1999–2018. TOXICS 12 (2024).
16. Quinones AR Prevalent multimorbidity combinations among middle-aged and older adults seen in community health centers J. Gen. Intern. Med. 2022 37 3545 10.1007/s11606-021-07198-2 35088201
Quinones, A. R. et al. Prevalent multimorbidity combinations among middle-aged and older adults seen in community health centers. J. Gen. Intern. Med. 37, 3545 (2022).35088201 10.1007/s11606-021-07198-2
17. Nagi, M. A. et al. Economic costs of obesity: A systematic review. Int. J. Obes. (2023).
18. Bridger SC Life course socioeconomic position and body composition in adulthood: A systematic review and narrative synthesis Int. J. Obes. 2021 45 2300 10.1038/s41366-021-00898-z
Bridger, S. C. et al. Life course socioeconomic position and body composition in adulthood: A systematic review and narrative synthesis. Int. J. Obes. 45, 2300 (2021).10.1038/s41366-021-00898-z
19. Kang, H. et al. Placental transfer and composition of perfluoroalkyl substances (PFASs): A Korean birth panel of parent-infant triads. TOXICS 9 (2021).
20. Mamsen LS Concentrations of perfluoroalkyl substances (PFASs) in human embryonic and fetal organs from first, second, and third trimester pregnancies Environ. Int. 2019 124 482 10.1016/j.envint.2019.01.010 30684806
Mamsen, L. S. et al. Concentrations of perfluoroalkyl substances (PFASs) in human embryonic and fetal organs from first, second, and third trimester pregnancies. Environ. Int. 124, 482 (2019).30684806 10.1016/j.envint.2019.01.010
21. Muller M Prenatal exposure to persistent organic pollutants in Northern Tanzania and their distribution between breast milk, maternal blood, placenta and cord blood Environ. Res. 2019 170 433 10.1016/j.envres.2018.12.026 30634139
Muller, M. et al. Prenatal exposure to persistent organic pollutants in Northern Tanzania and their distribution between breast milk, maternal blood, placenta and cord blood. Environ. Res. 170, 433 (2019).30634139 10.1016/j.envres.2018.12.026
22. Sun S Prenatal exposure to Per- and polyfluoroalkyl substances and adiposity measures of children at 4 and 6 years: A prospective birth cohort in China Ecotoxicol. Environ. Safe 2023 269 115751 10.1016/j.ecoenv.2023.115751
Sun, S. et al. Prenatal exposure to Per- and polyfluoroalkyl substances and adiposity measures of children at 4 and 6 years: A prospective birth cohort in China. Ecotoxicol. Environ. Safe 269, 115751 (2023).10.1016/j.ecoenv.2023.115751
23. Zhang M Associations of Prenatal Per- and Polyfluoroalkyl Substance (PFAS) Exposures with Offspring Adiposity and Body Composition at 16–20 Years of Age: Project Viva Environ. Health Perspect. 2023 131 127002 10.1289/EHP12597 38054701
Zhang, M. et al. Associations of Prenatal Per- and Polyfluoroalkyl Substance (PFAS) Exposures with Offspring Adiposity and Body Composition at 16–20 Years of Age: Project Viva. Environ. Health Perspect. 131, 127002 (2023).38054701 10.1289/EHP12597
24. US Centers for Disease Control and Prevention National Health and Nutrition Examination Survey (2023).
25. Webster J. B. et al., Income, Earnings, and Poverty Data from the 2005 American Community Survey (2005).
26. Wang Y Association between per- and polyfluoroalkyl substances exposure and prevalence of chronic obstructive pulmonary disease: The mediating role of serum albumin Sci. Total Environ. 2024 925 171742 10.1016/j.scitotenv.2024.171742 38494022
Wang, Y. et al. Association between per- and polyfluoroalkyl substances exposure and prevalence of chronic obstructive pulmonary disease: The mediating role of serum albumin. Sci. Total Environ. 925, 171742 (2024).38494022 10.1016/j.scitotenv.2024.171742
27. Guo J Association between polyfluoroalkyl substances exposure and sex steroids in adolescents: The mediating role of serum albumin Ecotoxicol. Environ. Safe 2023 253 114687 10.1016/j.ecoenv.2023.114687
Guo, J. et al. Association between polyfluoroalkyl substances exposure and sex steroids in adolescents: The mediating role of serum albumin. Ecotoxicol. Environ. Safe 253, 114687 (2023).10.1016/j.ecoenv.2023.114687
28. Tyrrell J Melzer D Henley W Galloway TS Osborne NJ Associations between socioeconomic status and environmental toxicant concentrations in adults in the USA: NHANES 2001–2010 Environ. Int. 2013 59 328 10.1016/j.envint.2013.06.017 23892225
Tyrrell, J., Melzer, D., Henley, W., Galloway, T. S. & Osborne, N. J. Associations between socioeconomic status and environmental toxicant concentrations in adults in the USA: NHANES 2001–2010. Environ. Int. 59, 328 (2013).23892225 10.1016/j.envint.2013.06.017
29. Buekers, J. et al., Socio-economic status and health: Evaluation of human biomonitored chemical exposure to per- and polyfluorinated substances across status. Int. J. Environ. Res. Public Health 15 (2018).
30. Nelson JW Scammell MK Hatch EE Webster TF Social disparities in exposures to bisphenol A and polyfluoroalkyl chemicals: A cross-sectional study within NHANES 2003–2006 Environ. Health-Glob. 2012 11 10
Nelson, J. W., Scammell, M. K., Hatch, E. E. & Webster, T. F. Social disparities in exposures to bisphenol A and polyfluoroalkyl chemicals: A cross-sectional study within NHANES 2003–2006. Environ. Health-Glob. 11, 10 (2012).
31. Bourguignon JP Rationale for Environmental Hygiene towards global protection of fetuses and young children from adverse lifestyle factors Environ. Health-Glob. 2018 17 42
Bourguignon, J. P. et al. Rationale for Environmental Hygiene towards global protection of fetuses and young children from adverse lifestyle factors. Environ. Health-Glob. 17, 42 (2018).
32. Ericson I Human exposure to perfluorinated chemicals through the diet: Intake of perfluorinated compounds in foods from the Catalan (Spain) market J. Agric. Food Chem. 2008 56 1787 10.1021/jf0732408 18251500
Ericson, I. et al. Human exposure to perfluorinated chemicals through the diet: Intake of perfluorinated compounds in foods from the Catalan (Spain) market. J. Agric. Food Chem. 56, 1787 (2008).18251500 10.1021/jf0732408
33. Fraser AJ Polyfluorinated compounds in serum linked to indoor air in office environments Environ. Sci. Technol. 2012 46 1209 10.1021/es2038257 22148395
Fraser, A. J. et al. Polyfluorinated compounds in serum linked to indoor air in office environments. Environ. Sci. Technol. 46, 1209 (2012).22148395 10.1021/es2038257
34. Pan K The relationship between perfluoroalkyl substances and hypertension: A systematic review and meta-analysis Environ. Res. 2023 232 116362 10.1016/j.envres.2023.116362 37295593
Pan, K. et al. The relationship between perfluoroalkyl substances and hypertension: A systematic review and meta-analysis. Environ. Res. 232, 116362 (2023).37295593 10.1016/j.envres.2023.116362
35. Aker A Cardiometabolic health and per and polyfluoroalkyl substances in an Inuit population Environ. Int. 2023 181 108283 10.1016/j.envint.2023.108283 37883911
Aker, A. et al. Cardiometabolic health and per and polyfluoroalkyl substances in an Inuit population. Environ. Int. 181, 108283 (2023).37883911 10.1016/j.envint.2023.108283
36. Wu M Zhu Z Wan R Xu J Exposure to per- and polyfluoroalkyl substance and metabolic syndrome: A nationally representative cross-sectional study from NHANES, 2003–2018 Environ. Pollut. 2024 346 123615 10.1016/j.envpol.2024.123615 38402937
Wu, M., Zhu, Z., Wan, R. & Xu, J. Exposure to per- and polyfluoroalkyl substance and metabolic syndrome: A nationally representative cross-sectional study from NHANES, 2003–2018. Environ. Pollut. 346, 123615 (2024).38402937 10.1016/j.envpol.2024.123615
